Details here: https://clinicaltrials.gov/study/NCT05968326

The "No prior treatments" part does not mean surgery. This is mainly for people who had PDAC tumors resected with clean margins in the last 6-12 weeks.

From the NCT link:

Inclusion Criteria:

Histologically confirmed diagnosis of PDAC
Pancreatic cancer tumor, lymph node, metastasis (TNM) pathological staging values of T1-T3, N0-N2, and M0 per the American Joint Committee on Cancer (AJCC) Cancer Staging Manual
Macroscopically complete (R0 or R1) resection of PDAC
Unequivocal absence of disease after surgery as assessed by the investigator within 28 days prior to randomization
CA19-9 level measured within 14 days prior to randomization
Interval of between 6 and 12 weeks since resection of PDAC
Full recovery from surgery and ability to receive atezolizumab, autogene cevumeran, and mFOLFIRINOX in the investigator's judgment
Adequate hematologic and end-organ function
Female participants of childbearing potential must be willing to avoid pregnancy during the treatment period and for 90 days after the final dose of autogene cevumeran, for 6 months after the last dose of chemotherapy, and for 5 months after the final dose of atezolizumab.
Male participants with a female partner of childbearing potential or pregnant female partner must remain abstinent or use specified contraceptive methods during the treatment period and for 28 days after the final dose of autogene cevumeran and for 6 months after the last dose of chemotherapy. Men must refrain from donating sperm during this same period.

Exclusion Criteria:

Prior adjuvant, neoadjuvant, or induction treatment for pancreatic cancer
Absence of spleen; distal pancreatectomy with splenectomy is exclusionary
Pregnancy or breastfeeding
Active or history of autoimmune disease or immune deficiency

---

I had been told (in consideration of a different study) that "No prior chemo" would not rule me out because all my Folfirinox was before surgery, which I came out of with clean margins and NED for 3 months. They treated my recurrence as if it were a new disease, but the study never materialized for me anyway.

However, this one does explicitly exclude "neoadjuvant" treatment (before surgery), so pretty narrow in scope. It's a possible win for the "surgery first" advocates.

Lots of subtle nuances in what the directors are looking for in any trial, so it's always good to ask and apply if appropriate. This one looks quite promising.